Multiple myeloma (MM) is a complex hematological malignancy with significant unmet needs. While conventional therapies have significantly improved patient survival, the disease remains incurable. A review, led by Qizhong Lu, Donghui Yang, Ting Niu, and Aiping Tong, explores the multifaceted nature of MM and the promising potential of targeted therapies.
The work is in the journal . The authors delve into the key signaling pathways that drive MM pathogenesis, including the PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, and NF-κB pathways. Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma .
The review provides a comprehensive overview of the roles of these pathways in MM, highlighting their potential as therapeutic targets. The authors also discuss the progress made in developing targeted immunotherapies for MM. This includes , ADCs, BsAbs, immune checkpoint inhibitors, CAR-T cells, CAR-NK cells, and TCR-T cells.
The review explores the mechanisms of action of these therapies, their efficacy in , and the challenges that remain in their development. Key findings from the review include: The authors conclude by emphasizing the need for continued research and development of targeted therapies for MM. They call for a focus on enhancing the specificity and efficacy of these therapies, developing more affordable treatment options, and investigating combination therapies to address resistance mechanisms.
They also emphasize the importance of personalizing treatment regimens for individual patients. Qizhong Lu et al, Multiple myeloma: signaling pathways and targeted therapy, (2024)..
